i 



i 



I 





Ihe Specific Treatment of 

 Lobar Pneumonia 



Immune serum treatment in lobar pneumonia has passed 

 the purely experimental stage. 



Lobar pneumonia is caused chiefly by the pneumococcus, 

 of which there are three different fixed types. Antipneumo- 

 coccic Serum prepared by the Mulford Laboratories is obtained 

 from horses which have been injected with the three fixed 

 types of the pneumococcus. 



Forty per cent of all cases of lobar pneumonia are caused 

 by type 1, and lobar pneumonia caused by this type is the 

 most amenable to serum treatment, while types 2 and 3 are 

 less amenable to serum treatment. Antipneumococcic Serum 

 Polyvalent Mulford is highly potent in its protective power 

 against lobar pneumonia caused by pneumococcus type 1, and 

 also contains antibodies to the other types — 2 and 3. 



Intravenous injection of 50 to 200 c.c. is advocated by prominent 

 authorities to insure immediate action. 



Antipneumococcic Serum Polyvalent Mulford is furnished in 

 syringes of 20 c.c. each, and in ampuls of 50 c.c. for intravenous injection. 



Further information sent on request. 



Pneumo-Serobacterin Mulford is an efficient prophylactic agent 

 against lobar pneumonia. Wright suggests doses of 1000 million pneumo- 

 cocci, followed by subsequent doses of 1000 million, for prophylactic 

 purposes. 



Pneumo-Serobacterin Mulford is supplied in packages of four 

 graduated syringes. A, B, C, D strength, and in syringes of D strength 

 separately. 



Syring-e A 250 million kilied sensitized bacteria 

 Syringe B 500 million killed sensitized bacteria 

 Syringe C 1000 million killed sensitized bacteria 

 Syringe D 2000 million killed sensitized bacteria 



P 



i 



i 





I 



I 



H. K. MULFORD COMPANY, Philadelphia, U. S. A. 



I 



i 



